AVIR Atea Pharmaceuticals, Inc.
USHealthcareAs of 2026-07-10 16:00
Why AVIR matters now
Atea Pharmaceuticals, Inc. (AVIR) is a US stock in Healthcare. The latest InvestLog snapshot shows $4.99 with +1.63% on the session and $399.3M in market capitalization; recent performance reads 1-month +5.06% and YTD +22.13%.
The latest financial table shown here is Q1 2026, with revenue of $0.00, net income of $-45.4M, and EPS of $-0.57. Investors can compare that operating picture with valuation signals such as P/E unavailable and FCF yield -42.4%.
The latest indexable market news headline is "Atea Pharmaceuticals Completes Patient Enrollment in Phase 3 C-FORWARD Trial Evaluating Bemnifosbuvir and Ruzasvir for Treatment of Hepatitis C Virus" from GlobeNewsWire.
Additional event context on this page matters because analyst consensus is Buy with a median target of $10.00; recent insider activity includes Murphy Polly A. filing P-Purchase. These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
—
PEG
—
P/B
1.48
P/S
0.00
EV/EBITDA
-1.50
DCF Value
$1.01
FCF Yield
-42.4%
Div Yield
0.0%
Margins & Returns
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-57.0%
ROA
-63.5%
ROIC
-78.1%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $0.00 | $-45.4M | $-0.57 |
| Q4 2025 | $0.00 | $-44.9M | $-0.57 |
| FY 2025 | $0.00 | $-158.3M | $-1.94 |
| Q3 2025 | $0.00 | $-42.0M | $-0.53 |
Analyst Ratings
Consensus
Buy
Target (Consensus)
$10.00
Target (Median)
$10.00
Target Range
$10.00 - $10.00
Trading Activity
Insider Trades
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Biotechnology
Country
US
Exchange
—
Beta
0.32
Atea Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical firm dedicated to the discovery, development, and commercialization of antiviral treatments for patients with viral infections. Its primary investigational drug, AT-527, is an antiviral currently undergoing Phase II clinical trials for the treatment of COVID-19. Beyond its lead candidate, Atea's development pipeline encompasses a range of other drug candidates. These include AT-752, an oral purine nucleoside prodrug that has completed Phase Ia clinical trials for dengue, and AT-777, an NS5A inhibitor. Atea is also advancing AT-787, which is a co-formulated, oral, pan-genotypic fixed-dose combination of AT-527 and AT-777 designed for hepatitis C virus (HCV) treatment. Additionally, AT-281, a pharmaceutically acceptable salt, is under investigation for its potential to treat or prevent RNA viral infections such as dengue fever, yellow fever, Zika virus, and coronaviridae. The company's portfolio further comprises Ruzasvir, an investigational oral, pan-genotypic NS5A inhibitor for chronic HCV infection. Atea maintains a license agreement with Merck & Co, Inc. for the development and commercialization of ruzasvir for HCV treatment. Established in 2012, Atea Pharmaceuticals, Inc. operates from its headquarters in Boston, Massachusetts.